本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 公司于 2025 年 10 月 17 日发出会议通知，并于 2025 年 10 月 29 日以现场结合通讯方式召开了 2025 年第四次监事会会议，会议应到 监事 3 名，实到监事 3 名。本次会议召开符合公司章程的有关规定， 经与会监事认真审议，形成如下决议： 一、审核公司 2025 年第三季度报告无误，并发表审核意见如下： 证券代码：600329 证券简称：达仁堂 编号：临 2025-036 号 津药达仁堂集团股份有限公司 2025 年第四次监事会决议公告 1．公司 2025 年第三季度报告的编制和审议程序符合法律、法规、 公司章程和公司内部管理制度的各项规定； 2．公司 2025 年第三季度报告的内容和格式符合中国证监会和证 券交易所的各项规定，所包含的信息从各个方面真实地反映出公司本 季度的经营管理和财务状况等事项； 2025 年 10 月 31 日 2 二、审核公司 2025 年前三季度利润分配预案无误。 监事会认为公司 2025 年前三季度利润分配预案符合中国证监会、 ...

证券代码：600329 证券简称：达仁堂 编号：临 2025-035 号 津药达仁堂集团股份有限公司 2025 年第六次董事会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药达仁堂集团股份有限公司于 2025 年 10 月 17 日发出会议通 知，并于 2025 年 10 月 29 日以现场结合通讯方式召开了 2025 年第六 次董事会会议。本次会议应参加董事 9 人，实参加董事 9 人。会议召 开符合《公司法》、《证券法》和《公司章程》有关召开董事会会议的 规定。会议形成如下决议： 一、审议通过了公司 2025 年中国准则第三季度报告与国际准则 的第三季度报告。 据本公司董事会全体成员及管理层所知，没有任何其他信息将致 使该报告不确实或具有误导性。 本议案已经公司董事会审计委员会审议通过。 表决结果：同意 9 票，反对 0 票，弃权 0 票 二、审议通过了《关于修订<公司章程>并办理工商变更的议案》。 （详见临时公告 2025-037 号） 经董事会审阅，认为本次对《公司章程》中取消监事会，原监事 会法定职权由 ...

证券代码：600329 证券简称：达仁堂 编号：临 2025-039 号 津药达仁堂集团股份有限公司 2025 年前三季度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配预案内容 （一）利润分配预案的具体内容 截至 2025 年 9 月 30 日，本公司母公司报表期末未分配利润为 6,577,352,140.60 元人民币（未经审计）。经董事会决议，公司拟以实 施权益分派股权登记日登记的总股本为基数，实施 2025 年前三季度 利润分配。本次利润分配方案如下： 2025 年三季度末，公司拟进行利润分配，以实施权益派息股权 登记日总股本为基数，向全体股东每 10 股派发现金红利 24.50 元人 民币（含税）。截至 2025 年 9 月 30 日，公司总股本 770,094,356 股（其 中，A 股 570,094,356 股，S 股 200,000,000 股），以此计算合计拟派 发现金红利 1,886,731,172.20 元人民币（含税）。本次公司现金分红 占公司2025 ...

Financial Performance - The company's operating revenue for the third quarter was CNY 1,019,342,255.45, a decrease of 38.08% year-on-year[4] - Total profit for the quarter reached CNY 253,188,070.04, an increase of 44.05% compared to the same period last year[4] - Net profit attributable to shareholders was CNY 224,559,220.11, reflecting a year-on-year increase of 53.66%[4] - Basic earnings per share for the quarter were CNY 0.30, an increase of 57.89% compared to the same period last year[5] - Total profit for the year-to-date increased by 172.92%, primarily due to the sale of a 12% stake in a joint venture, generating a disposal gain of 1.54 billion RMB after tax[10] - Net profit for the first three quarters of 2025 reached CNY 2,146,216,262.92, compared to CNY 793,134,205.47 in 2024, reflecting an increase of approximately 171.5%[19] - Operating profit for the first three quarters of 2025 was CNY 2,522,594,956.81, significantly higher than CNY 919,432,930.61 in the previous year, marking an increase of around 174.3%[19] - The net profit attributable to the parent company shareholders for the first three quarters of 2025 is CNY 2,152,182,184.52, compared to CNY 803,855,815.93 in the same period of 2024, representing a significant increase[20] - The total comprehensive income for the first three quarters of 2025 is CNY 2,145,311,321.48, up from CNY 792,454,029.76 in 2024[20] - Basic and diluted earnings per share for the first three quarters of 2025 are both CNY 2.80, compared to CNY 1.04 in 2024, indicating a strong performance improvement[20] Cash Flow - The cash flow generated from operating activities amounted to CNY 102,588,569.58, a significant increase of 727.70% year-on-year[4] - The net cash flow from operating activities increased by 727.70% for the current reporting period, mainly due to a rise in cash received from sales of goods and services[10] - Cash inflows from operating activities for the first three quarters of 2025 amount to CNY 3,640,002,364.59, down from CNY 6,200,789,712.62 in 2024[21] - The net cash flow from operating activities for the first three quarters of 2025 is CNY 590,329,947.27, slightly up from CNY 567,609,005.34 in 2024[21] - Cash outflows from investing activities for the first three quarters of 2025 total CNY 5,010,758,565.34, compared to CNY 1,391,606,362.08 in 2024, indicating increased investment activity[22] - The net cash flow from investing activities for the first three quarters of 2025 is -CNY 1,506,491,600.39, worsening from -CNY 1,175,618,836.51 in 2024[22] - The net cash flow from financing activities for the first three quarters of 2025 is -CNY 979,528,249.55, compared to -CNY 31,519,702.29 in 2024, reflecting a significant increase in cash outflows[22] - The ending cash and cash equivalents balance as of the end of the third quarter of 2025 is CNY 1,048,684,858.24, down from CNY 1,357,743,974.78 in 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were CNY 11,585,156,807.98, representing a 7.58% increase from the end of the previous year[5] - Total assets as of September 30, 2025, were CNY 11,585,156,807.98, compared to CNY 10,768,625,044.29 at the end of 2024, reflecting an increase of about 7.6%[15] - Total liabilities decreased to CNY 2,561,059,550.26 as of September 30, 2025, from CNY 2,918,688,717.32 at the end of 2024, a decline of approximately 12.3%[16] - Shareholders' equity attributable to the company was CNY 9,009,343,064.30, up 14.86% from the previous year-end[5] - Shareholders' equity increased to CNY 9,024,097,257.72 as of September 30, 2025, compared to CNY 7,849,936,326.97 at the end of 2024, representing an increase of about 14.9%[16] Product Sales - The sales revenue of the main product, Su Xiao Xin Xin Wan, was CNY 1.716 billion, up 13.34% year-on-year[6] - The sales revenue of Qing Yan Di Wan reached CNY 376 million, marking a year-on-year growth of 38.61%[6] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 58,613[12] - The largest shareholder, Tianjin Pharmaceutical Group Co., Ltd., holds 331,120,528 shares, accounting for 42.997% of total shares[12] Accounting and Reporting Changes - The company plans to divest its wholly-owned subsidiary Tianjin Zhongxin Pharmaceutical Co., Ltd., which will impact revenue recognition in future reports[6] - Operating revenue for the current reporting period decreased by 38.08%, primarily due to changes in the scope of consolidation, as Tianjin Zhongxin Pharmaceutical Co., Ltd. is no longer included in the data[10] - The company will not apply new accounting standards starting from 2025, as stated in the announcement[23]

津药达仁堂集团股份有限公司 章 程 二零二五年十月二十九日 | | | | 第一章 | 总则………………………………………………………………………3 | | --- | --- | | 第二章 | 经营宗旨和范围…………………………………………………………4 | | 第三章 | 股份和注册资本…………………………………………………………5 | | 第四章 | 减资和购回股份…………………………………………………………9 | | 第五章 | 购买公司股份的财务资助………………………………………………12 | | 第六章 | 股份转让…………………………………………………………………13 | | 第七章 | 股票和股东名册…………………………………………………………14 | | 第八章 | 股东的权利和义务………………………………………………………18 | | 第九章 | 股东大会…………………………………………………………………23 | | 第十章 | 类别股东表决的特别程序………………………………………………38 | | 第十一章 | 党的组织…………………………………………………………40 | | 第十二章 ...

Market Performance - The market experienced a rebound last week, with the CSI Xinhua National Brand Index rising by 4.14% to 2037.67 points [1][2] - The Shanghai Composite Index increased by 2.88%, the Shenzhen Component Index by 4.73%, the ChiNext Index by 8.05%, and the CSI 300 Index by 3.24% [2] Strong Stock Performances - Notable strong performers included: - Zhongji Xuchuang (up 32.23%) - Shiyuan Technology (up 14.54%) - Sunshine Power (up 14.37%) [2] - Other stocks with significant gains included: - Anji Technology and Wowo Bio (both up over 10%) - SMIC and Zhaoyi Innovation (both up over 9%) [2] Year-to-Date Stock Performance - Since the beginning of the second half of the year, Zhongji Xuchuang has surged by 239.03%, leading the gains [3] - Sunshine Power has increased by 145.06%, while other stocks like Lanke Technology and Yiwei Lithium Energy have risen over 70% [3] Market Outlook - According to Fangzheng Fubang Fund, liquidity remains a crucial driver for market development, and future capital inflow will significantly impact market trends [4] - The fund suggests focusing on sectors with solid fundamentals and reasonable valuations, rather than chasing high-performing stocks with poor earnings [4] - Long-term investment opportunities may lie in technology companies with real technological barriers that align with national strategies [4] - Kangmand Capital anticipates a volatile market in the short term due to uncertainties, but the core logic for an upward trend remains unchanged [4] - Xingshi Investment notes that positive incremental information could stabilize market expectations and emotions, with a potential shift in economic momentum towards technology and consumption [4]

Market Overview - The Chinese medicine sector experienced a decline of 0.34% on October 23, with Zhongsheng Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Stock Performance - Notable gainers included: - Qidi Pharmaceutical (Code: 000590) with a closing price of 12.68, up 9.97% and a trading volume of 261,000 shares, totaling 320 million yuan [1] - Zhendong Pharmaceutical (Code: 300158) closed at 7.32, up 4.27% with a trading volume of 1,012,600 shares, totaling 753 million yuan [1] - Major decliners included: - Zhongsheng Pharmaceutical (Code: 002317) closed at 18.43, down 4.75% with a trading volume of 569,600 shares, totaling 1.056 billion yuan [2] - Darentang (Code: 600329) closed at 43.15, down 3.68% with a trading volume of 75,800 shares, totaling 328 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 897 million yuan from institutional investors, while retail investors contributed a net inflow of 989 million yuan [2] - The table of capital flow indicates that: - Qidi Pharmaceutical had a net inflow of 23.93 million yuan from institutional investors, while retail investors had a net outflow of 25.84 million yuan [3] - Zhendong Pharmaceutical experienced a net inflow of 19.97 million yuan from institutional investors, with retail investors seeing a net outflow of 2.25 million yuan [3]

Core Viewpoint - The Chinese medicine sector is experiencing a mixed performance, with the Chinese medicine ETF (560080) showing significant net inflows and a growing fund size, despite the overall index performance being negative for the year [1][4]. Group 1: Market Performance - The Chinese medicine ETF (560080) saw a slight decline of 0.46% with a total trading volume of 116 million yuan on the day [1]. - The ETF has attracted a net inflow of 192 million yuan yesterday, ranking it among the top 9 in the market, and has seen a total net inflow exceeding 600 million yuan over the past 16 days [1]. - The Chinese medicine index has a year-to-date return of -2.53%, with a decline of 8.13% projected for 2024 [3]. Group 2: Valuation Metrics - As of October 22, the TTM price-to-earnings (PE) ratio of the Chinese medicine ETF (560080) is 25.22, indicating that the index is cheaper than 77% of the time over the past decade [4]. - The current PE ratio is close to the calculated opportunity value, suggesting a favorable valuation for potential investment [4]. Group 3: Company Performance - The component stocks of the Chinese medicine ETF exhibited mixed results, with companies like Yunnan Baiyao and Pianzaihuang showing slight increases, while others like Zhongsheng Pharmaceutical and Darentang experienced declines exceeding 4% [5]. - The performance of major brands in the OTC market is expected to improve, with companies like Huazhong Sanjiu, Dong'e Ejiao, and Yunnan Baiyao being highlighted as stable performers [8]. Group 4: Industry Outlook - The Chinese medicine sector is under short-term pressure due to various factors, but there is optimism for operational improvements in the second half of the year [7]. - The market is closely monitoring the impact of external policies, including price governance and the collection of traditional Chinese medicine, which may influence future performance [7][9]. - The industry is expected to benefit from a recovery in consumer demand, driven by macroeconomic improvements and an aging population [10].

Core Viewpoint - The market experienced a correction last week, but certain stocks within the brand index showed resilience, indicating potential investment opportunities in sectors like electronics, new energy, new consumption, and real estate as uncertainties ease [1][4]. Market Performance - The market indices saw declines: Shanghai Composite Index down 1.47%, Shenzhen Component down 4.99%, ChiNext down 5.71%, and CSI 300 down 2.22%. The brand index fell 3.58% to 1956.62 points [2]. - Notable gainers in the brand index included Shanghai Jahwa up 9.42%, Changbai Mountain up 7.19%, and Darentang up 5.34%. Other stocks like Luzhou Laojiao and Yiling Pharmaceutical also saw gains exceeding 4% [2]. Stock Performance Since H2 - Since the beginning of the second half of the year, Zhongji Xuchuang has surged 156.40%, leading the gains, followed by Sunshine Power at 114.27%. Other significant performers include Lanke Technology and Yiwei Lithium Energy, both up over 60% [3]. Market Outlook - Looking ahead, the market is expected to maintain upward momentum as uncertainties gradually diminish. Liquidity is anticipated to remain supportive, with domestic interest rates low and overseas liquidity remaining loose, encouraging investment in Chinese equity assets [4][5]. - The current market environment is characterized by a shift in investment styles, with a focus on sectors that offer higher investment certainty, particularly in electronics, new energy, new consumption, and real estate [5].

Group 1 - The core index of the Xinhua National Brand Project reported 1956.62 points, with several constituent stocks rising against the market trend [1] - Shanghai Jahwa increased by 9.42%, leading the gains among constituent stocks, followed by Changbaishan at 7.19% and Darentang at 5.34% [1] - The overall market saw declines, with the Shanghai Composite Index down 1.47% and the Shenzhen Component Index down 4.99% [1] Group 2 - Since the second half of the year, Zhongji Xuchuang has risen by 156.40%, ranking first in gains, followed by Sunshine Power at 114.27% [2] - The market is expected to maintain upward momentum, with liquidity driving potential growth and fundamental support gradually increasing [2] - Domestic interest rates remain low, and overseas liquidity is expected to remain loose, indicating continued capital allocation towards Chinese equity assets [2] Group 3 - Recent market adjustments are attributed to a decline in global market risk appetite and a shift in investment style towards defensive sectors [3] - The current market environment is characterized by high levels, increased uncertainty, and a slowdown in previous catalysts, leading to cautious trading [3] - Investors are encouraged to seek opportunities in sectors with higher investment certainty, particularly in electronics, new energy, new consumption, and real estate [3]